Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 5,120,000 shares, agrowthof159.9% from the June 30th total of 1,970,000 shares. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is presently 3.3 days. Based on an average trading volume of 1,570,000 shares, the days-to-cover ratio is presently 3.3 days.

Milestone Pharmaceuticals Stock Performance

NASDAQ:MIST traded down $0.02 during mid-day trading on Thursday, hitting $1.52. 501,628 shares of the company traded hands, compared to its average volume of 1,776,548. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $2.75. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06. The firm has a market cap of $81.00 million, a price-to-earnings ratio of -1.94 and a beta of 0.52. The stock's fifty day moving average price is $1.72 and its 200-day moving average price is $1.62.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Research analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIST. Bay Rivers Group purchased a new position in Milestone Pharmaceuticals in the 2nd quarter worth approximately $28,000. National Bank of Canada FI lifted its holdings in shares of Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company's stock worth $44,000 after buying an additional 11,600 shares in the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth $73,000. XTX Topco Ltd purchased a new position in Milestone Pharmaceuticals during the fourth quarter valued at $80,000. Finally, Northern Trust Corp grew its stake in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company's stock valued at $137,000 after acquiring an additional 30,772 shares in the last quarter. 86.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright raised Milestone Pharmaceuticals to a "buy" rating and set a $5.00 price objective for the company in a report on Thursday, June 5th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $7.00.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.